IFN/imatinib induction treatment followed by a temporary IFN maintenance may enable a higher rate of treatment discontinuation in CML patients in at least MMR when stopping TKI (140). The gene discussed is IFNA1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.